Mevlyq

Eribulin mesylate, the active ingredient in Mevlyq, is a microtubule inhibitor presented as an intravenous formulation for use in oncology patients. It is indicated for the treatment of metastatic breast cancer and for unresectable or metastatic liposarcoma.

GNH USA supplies Mevlyq as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for clinical use. Our distribution network ensures timely delivery across Europe, Asia, Africa and the Americas, supporting patient access to advanced cancer therapies.

Mevlyq (eribulin mesylate) is a microtubule‑targeting antineoplastic used in specific solid‑tumor indications.

Metastatic breast cancer (post‑anthracycline and taxane): improves overall survival and disease control in patients with previously treated disease. Unresectable or metastatic liposarcoma (advanced disease): provides tumor shrinkage and progression‑free survival in patients with advanced disease. Advanced solid tumours (clinical study): demonstrated antitumor activity in phase II trials, supporting its role in oncology research.

Mevlyq may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Neutropenia: decreased white blood cell count, increasing infection risk. - Fatigue: persistent tiredness affecting daily activities. - Alopecia: hair loss that may be temporary. - Nausea: feeling of sickness often managed with anti‑emetics. - Peripheral neuropathy: tingling or numbness in extremities. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophil count, requiring urgent care. - Cardiac toxicity: reduced left‑ventricular function or arrhythmias. - Pulmonary embolism: blood clot in the lungs, presenting with sudden shortness of breath. - Severe infection: sepsis or opportunistic infections due to immunosuppression. - Tumor lysis syndrome: rapid tumor breakdown causing metabolic disturbances.

When using Mevlyq, several safety considerations should be observed.

Monitor blood counts: perform regular CBC to detect neutropenia. Assess hepatic function: adjust use in patients with liver impairment. Evaluate peripheral neuropathy: discontinue if severe symptoms develop. Avoid concurrent myelosuppressive agents: increased risk of bone‑marrow suppression. Pregnancy and breastfeeding: safety unknown; avoid use unless benefits outweigh risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Eribulin mesylate can affect or be affected by other medicines.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase eribulin exposure. - Concurrent myelosuppressive chemotherapy (e.g., paclitaxel): heightened risk of severe neutropenia.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampin): may reduce eribulin efficacy. - Anticoagulants (e.g., warfarin): monitor for bleeding due to platelet effects. - Live vaccines: immunosuppression may diminish vaccine effectiveness.